Form 4: Janux CBO Exercises Options, Sells Shares

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, exercised stock options and sold a portion of the resulting common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, Inc., executed transactions on November 14, 2025.
• Exercised stock options to acquire 3,333 shares of Common Stock at an exercise price of $10.59 per share.
• Sold 3,333 shares of Common Stock at a price of $30.00 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
• Following these transactions, Meyer beneficially owns 84,974 shares of Common Stock directly.
• Meyer also beneficially owns 118,101 stock options.
• Beneficial ownership of common stock includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 15, 2024, and 2,834 shares acquired under the Plan on May 15, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine for an executive, demonstrating a planned liquidity event and a significant gain, which can be seen as positive for the individual. However, any insider selling can be viewed with slight caution, though mitigated by the 10b5-1 plan.

Positives

• The officer realized a significant gain, selling shares at $30.00 after exercising options at $10.59, indicating personal financial success from company equity.
• The transaction was executed under a Rule 10b5-1 trading plan, suggesting a pre-planned liquidity event rather than a reaction to new, undisclosed material information.

Negatives

• An officer selling shares, even under a pre-arranged plan, can sometimes be perceived with slight caution by investors as it reduces their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event not based on new material non-public information.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are a routine part of executive compensation and personal financial planning across all industries. The use of a Rule 10b5-1 plan is a common practice to manage such transactions in compliance with insider trading regulations.

Comparison to Industry Standards

• This transaction is a standard disclosure for an insider exercising options and selling shares, consistent with corporate governance practices in publicly traded companies.
• The use of a Rule 10b5-1 plan aligns with best practices for executives to manage their equity holdings while avoiding accusations of trading on material non-public information, a standard adopted by many peers in the biotechnology sector.

Stakeholder Impact

• Shareholders: May observe an officer reducing direct share ownership, but the pre-arranged 10b5-1 plan mitigates concerns about the timing of the sale. The officer still retains a significant number of shares and options, maintaining alignment with shareholder interests.

Next Steps

• The remaining stock options held by the reporting person will expire on May 13, 2031, if not exercised before then.

Key Dates

Recommendation

This is a routine insider transaction (exercise and sell) executed under a pre-arranged 10b5-1 plan. While an officer selling shares might sometimes raise questions, the pre-planned nature and the fact that the officer still retains a substantial number of shares and options suggest it's a personal liquidity event rather than a signal of negative company prospects. It does not provide new fundamental information to change an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Janux Therapeutics, JANX, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Andrew Hollman Meyer, Chief Business Officer, Equity Sales